Department of Respiratory Medicine, The Second Hospital Affiliated to Dalian Medical University, Dalian, China.
BMC Biotechnol. 2013 Sep 27;13:76. doi: 10.1186/1472-6750-13-76.
The development of early and personalized diagnostic protocols is considered the most promising avenue to decrease mortality from cancer and improve outcome. The emerging microfluidic-based analyzing platforms hold high promises to fulfill high-throughput and high-precision screening with reduced equipment cost and low analysis time, as compared to traditional bulky counterparts in bench-top laboratories. This article overviewed the potential applications of microfluidic technologies for detection and monitoring of cancer through nucleic acid and protein biomarker analysis. The implications of the technologies in cancer cytology that can provide functional personalized diagnosis were highlighted. Finally, the future niches for using microfluidic-based systems in tumor screening were briefly discussed.
早期和个性化诊断方案的开发被认为是降低癌症死亡率和改善预后的最有前途的途径。与传统台式实验室中的大型仪器相比,新兴的基于微流控的分析平台具有很高的潜力,可以实现高通量和高精度的筛选,同时降低设备成本和缩短分析时间。本文综述了微流控技术在通过核酸和蛋白质生物标志物分析检测和监测癌症方面的潜在应用。强调了该技术在提供功能个性化诊断的癌症细胞学中的应用。最后,简要讨论了基于微流控的系统在肿瘤筛查中的未来应用领域。